Kalaris Therapeutics, Inc. (KLRS) - Total Liabilities
Based on the latest financial reports, Kalaris Therapeutics, Inc. (KLRS) has total liabilities worth $39.31 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore cash flow conversion of Kalaris Therapeutics, Inc. to assess how effectively this company generates cash.
Kalaris Therapeutics, Inc. - Total Liabilities Trend (2018–2024)
This chart illustrates how Kalaris Therapeutics, Inc.'s total liabilities have evolved over time, based on quarterly financial data. Check financial resilience of Kalaris Therapeutics, Inc. to evaluate the company's liquid asset resilience ratio.
Kalaris Therapeutics, Inc. Competitors by Total Liabilities
The table below lists competitors of Kalaris Therapeutics, Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Right Way Industrial Co Ltd
TW:1506
|
Taiwan | NT$370.80 Million |
|
Taiwan IC Packaging
TWO:3372
|
Taiwan | NT$299.21 Million |
|
Chyang Sheng Dyeing & Finishing Co Ltd
TW:1463
|
Taiwan | NT$752.75 Million |
|
Beta Systems Software AG
F:BSS
|
Germany | €42.16 Million |
|
Rama Steel Tubes Limited
NSE:RAMASTEEL
|
India | Rs3.69 Billion |
|
Powerwell Holdings Bhd
KLSE:0217
|
Malaysia | RM68.20 Million |
|
Star Holdings
NASDAQ:STHO
|
USA | $304.33 Million |
|
Tillys Inc
NYSE:TLYS
|
USA | $225.62 Million |
Liability Composition Analysis (2018–2024)
This chart breaks down Kalaris Therapeutics, Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Kalaris Therapeutics, Inc. market cap and net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 12.89 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.94 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.48 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Kalaris Therapeutics, Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Kalaris Therapeutics, Inc. (2018–2024)
The table below shows the annual total liabilities of Kalaris Therapeutics, Inc. from 2018 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $5.24 Million | -89.16% |
| 2023-12-31 | $48.35 Million | +41.49% |
| 2022-12-31 | $34.17 Million | -44.28% |
| 2021-12-31 | $61.33 Million | +245.37% |
| 2020-12-31 | $17.76 Million | -0.23% |
| 2019-12-31 | $17.80 Million | +376.26% |
| 2018-12-31 | $3.74 Million | -- |
About Kalaris Therapeutics, Inc.
Kalaris Therapeutics, Inc., a clinical-stage ophthalmology biotech company, engages in developing therapies for the treatment of neovascular retinal diseases. Kalaris Therapeutics, Inc. was formerly known as Theia Therapeutics, Inc. and changed its name to Kalaris Therapeutics, Inc. in May 2024. The company was incorporated in 2019 and is based in Palo Alto, California.